Gallo Giuseppe, Mastorino Luca, Tonella Luca, Ribero Simone, Quaglino Pietro
Dermatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
Clin Exp Vaccine Res. 2022 Jan;11(1):129-132. doi: 10.7774/cevr.2022.11.1.129. Epub 2022 Jan 31.
The coronavirus disease 2019 (COVID-19) vaccines are authorized for use in numerous countries worldwide. Several cutaneous findings are reported after severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccination. Here, we report the case of a patient with a rapid onset of alopecia areata immediately after receiving the second dose of the COVID-19 vaccine. Alopecia areata is a common autoimmune disease leading to non-scarring hair loss. Among the many cutaneous adverse effects reported after the anti-SARS-COV2 vaccination, no episodes of alopecia areata have been described to date. In this paper, we report the first case of alopecia areata after COVID-19 vaccination described in the literature with a revision of cases of alopecia areata reported after other types of vaccination. Although the significance of these skin reactions is not yet known, further studies will certainly clarify whether the development of alopecia areata or other forms of immune-mediated reactions could represent a positive prognostic factor regarding immune protection from SARS-CoV-2.
2019冠状病毒病(COVID-19)疫苗已在全球众多国家获得使用授权。在接种严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗后,有多项皮肤表现的报告。在此,我们报告一例患者在接种第二剂COVID-19疫苗后迅速出现斑秃的病例。斑秃是一种常见的自身免疫性疾病,可导致非瘢痕性脱发。在抗SARS-CoV-2疫苗接种后报告的众多皮肤不良反应中,迄今为止尚未有斑秃发作的描述。在本文中,我们报告了文献中描述的首例COVID-19疫苗接种后斑秃病例,并对其他类型疫苗接种后报告的斑秃病例进行了回顾。尽管这些皮肤反应的意义尚不清楚,但进一步的研究必将阐明斑秃或其他形式的免疫介导反应的发生是否可能代表对SARS-CoV-2免疫保护的积极预后因素。